TY - JOUR A1 - Raschig, Martina A1 - Ramírez‐Zavala, Bernardo A1 - Wiest, Johannes A1 - Saedtler, Marco A1 - Gutmann, Marcus A1 - Holzgrabe, Ulrike A1 - Morschhäuser, Joachim A1 - Meinel, Lorenz T1 - Azobenzene derivatives with activity against drug‐resistant Candida albicans and Candida auris JF - Archiv der Pharmazie N2 - Increasing resistance against antimycotic drugs challenges anti‐infective therapies today and contributes to the mortality of infections by drug‐resistant Candida species and strains. Therefore, novel antifungal agents are needed. A promising approach in developing new drugs is using naturally occurring molecules as lead structures. In this work, 4,4'‐dihydroxyazobenzene, a compound structurally related to antifungal stilbene derivatives and present in Agaricus xanthodermus (yellow stainer), served as a starting point for the synthesis of five azobenzene derivatives. These compounds prevented the growth of both fluconazole‐susceptible and fluconazole‐resistant Candida albicans and Candida auris strains. Further in vivo studies are required to confirm the potential therapeutic value of these compounds. KW - antifungal drug KW - azobenzenes KW - Candida auris KW - Candida albicans Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-312295 VL - 356 IS - 2 ER - TY - THES A1 - Ebner, Sebastian Manfred T1 - Antimykotikaresistenzen bei deutschen \(Candida\) \(auris\) Isolaten T1 - Antimycotic resistance in German \(Candida\) \(auris\) isolates N2 - Bei dem 2009 erstbeschriebenen Hefepilz C. auris handelt es sich um einen Keim, welcher aufgrund von nosokomialen Ausbrüchen und hohen Antimykotikaresistenzen Aufmerksamkeit erregte. Ziel dieser Arbeit war es in Deutschland gesammelte Isolate bezüglich vorhandener Resistenzen und Mutationen in Resistenzregionen zu testen und das epidemiologische Geschehen hierzulande mit dem globalen Auftreten des Keims zu vergleichen. Bezüglich der durchgeführten Resistenztestungen wiesen die CLSI-konformen Testarten (YO-Platten und E-Test-Verfahren) meist vergleichbare Ergebnisse auf. Für das EUCAST-konforme Mikrodilutionstestverfahren kann aufgrund eines stark ausgeprägten paradoxen Wachstumseffekts nur Anidulafungin, nicht jedoch Caspofungin, zur Testung empfohlen werden. Insgesamt erwiesen sich 25 % der Isolate als Caspofungin-resistent. Zwei Isolate zeigten eine Resistenz gegenüber allen getesteten Echinocandinen (16,7 %). Die höchsten Resistenzraten wurden gegenüber Fluconazol (92 %) beobachtet. Zwei der Isolate zeigten sich gegenüber Voriconazol resistent (16,7 %). Für Amphotericin B konnte eine Resistenzrate von 33,3 % festgestellt werden. Für die Wirkstoffe Posaconazol und Itraconazol erwiesen sich alle untersuchten Isolate als sensitiv. Dies konnte auch mit Ausnahme eines Isolates für 5-Flucytosin beobachtet werden. Die durch eine Sanger-Sequenzierung erhaltenen Sequenzen der Gene FKS1 und ERG11 wurden auf Mutationen untersucht, welche zu Aminosäuresubstitutionen im Gesamtprotein führten. Hierbei ergaben sich für zwei Isolate (16,7 %) Mutationen im FKS1-Hot Spot 1 (Typ S639F und S639Y). Beide Isolate zeigten sich in den AFST Echinocandin-resistent. Bei allen untersuchten Isolaten lagen Mutationen im ERG11 Gen vor. So fand sich in 8 Fällen eine Mutation des Typen Y132F (66,7 %), in 3 Fällen der Typ K143R (25 %) und in einem Fall der Typ F126L (8,3 %). Im Rahmen eines anderen Projekts wurde mit den hier gewonnenen PCR-Produkten ein WGS durchgeführt, um die Isolate durch SNPs-Vergleich mit Referenzstämmen phylogenetischen Clades zuzuordnen. Dabei konnten 91,7 % der Isolate dem südasiatischen Clade I und ein Isolat dem südafrikanischen Clade III zugeordnet werden. Aufgrund der geringen epidemiologischen Fallzahlen in Deutschland scheint gegenwärtig keine Bedrohung von C. auris auszugehen. Berichte aus anderen Ländern konnten allerdings eine rasche, ausbruchartige Zunahme von C. auris Fällen nachweisen. So kann nur angeraten werden das infektiologische Geschehen in Deutschland weiterhin zu beobachten. N2 - The fungus C. auris was first described in the year 2009. Because of a high number of nosocomial outbrakes and high antimycotic resistance rates the fungus attracted great media attention. The aim of this dissertion was to test German isolates for antimycotic resistance and mutations in resistance genes. Additionally, the epidemiological occurrence in Germany was compared to the global outspread. In this context CLSI-conform methods for resistance testing (YO-Plates and E-Test-Plates) generated comparable results. The testing of EUCAST-conform microdilution plates showed a strong paradoxical growth for Caspofungin. Because of this only Anidulafungin can be recommended for testing. In summary 25 % of the isolates were resistant against Caspofungin. Two isolates showed resistance against all tested Echinocandines (16,7 %). The highest rates were detected for Fluconazol (92 %). Furthermore, two of the isolates (16,7 %) showed resistance against Voriconazol. There was a resistance rate of 33,3 % to Amphotericin B. No isolate showed resistance against Posaconazol or Itraconazol. And only one isolate was resistant against 5-Flucytosin. Sanger-Sequencing was used to detect mutations in resistance genes FKS1 und ERG11, which could lead to a substitution of amino acids in the protein. There were two isolates (16,7 %) with mutations in FKS1-Hot Spot 1 (type S639F and S639Y). Both isolates showed a Echinocandin resistance in AFST. All tested isolates showed a mutation in ERG11. There were eight cases of type Y132F (66,7 %), three cases of K143R (25 %) and in one case type F126L (8,3 %). The PCR products of this study were used in a different project for WSG. This made it possible to group the isolates into phylogenetic clades. In summary 91,7 % of the isolates were related to Clade I (South Asia) and one isolate was related to Clade III (South Africa). Because of low epidemiologic occurence in Germany, there is little threat of servere health care issues at the moment. Reports from diffferent countries all over the world however, showed a quick, outbrake-like increase of C. auris cases. Therefore, further observation of German epidemiology is highly recommended. KW - Candida KW - Resistenz KW - Wirkstoff KW - Behandlung KW - Antimykotikaresistenz KW - Candida auris KW - Resistance mechanism C. auris KW - Mutation FKS Hot Spot 1/ERG11 KW - Nosokomiale Infektion KW - E-Test KW - Mikrodilutionstest KW - Hospitalismus KW - Pilz Y1 - 2023 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318068 ER - TY - JOUR A1 - Aldejohann, Alexander Maximilian A1 - Wiese-Posselt, Miriam A1 - Gastmeier, Petra A1 - Kurzai, Oliver T1 - Expert recommendations for prevention and management of Candida auris transmission JF - Mycoses N2 - Candida auris was first described as a yeast pathogen in 2009. Since then, the species has emerged worldwide. In contrast to most other Candida spp., C. auris frequently exhibits multi-drug resistance and is readily transmitted in hospital settings. While most detections so far are from colonised patients, C. auris does cause superficial and life-threatening invasive infections. During management of the first documented C. auris transmission in a German hospital, experts from the National Reference Centers for Invasive Fungal Infections (NRZMyk) and the National Reference Center for Surveillance of Nosocomial Infections screened available literature and integrated available knowledge on infection prevention and C. auris epidemiology and biology to enable optimal containment. Relevant recommendations developed during this process are summarised in this guidance document, intended to assist in management of C. auris transmission and potential outbreak situations. Rapid and effective measures to contain C. auris spread require a multi-disciplinary approach that includes clinical specialists of the affected unit, nursing staff, hospital hygiene, diagnostic microbiology, cleaning staff, hospital management and experts in diagnostic mycology / fungal infections. Action should be initiated in a step-wise process and relevant interventions differ between management of singular C. auris colonised / infected patients and detection of potential C. auris transmission or nosocomial outbreaks. KW - Candida auris KW - nosocomial transmission KW - infection prevention KW - expert recommendation Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-318570 VL - 65 IS - 6 SP - 590 EP - 598 ER - TY - THES A1 - Stieber, Hanna T1 - Auswirkungen des Sphingolipidsynthese-Inhibitors Myriocin auf Vitalität und Antimykotikaresistenz von \(Candida\) \(auris\) T1 - Impact of the sphingolipid synthesis inhibitor myriocin on viability and antifungal susceptibility of \(Candida\) \(auris\) N2 - Candida Spezies gehören als kommensale Organismen zur normalen menschlichen Mikroflora, können allerdings unter bestimmten Bedingungen Krankheitswert erlangen. Limitationen in der Behandlung durch immer mehr resistente Candida Spezies und die wachsende Zahl immunsupprimierter Patienten gelten als Hauptursachen für die steigende Häufigkeit invasiver Candidosen und systemischer Candidämien. Die 2009 entdeckte Spezies C. auris stellt durch ihre zahlreichen Resistenzen, das Potential zur Auslösung nosokomialer Ausbrüche in Krankenhäusern und die schnelle Verbreitung über mehrere Kontinente eine neue Herausforderung dar. Der Bedarf an neuen Antimykotika mit anderen Wirkmechanismen und neuen Zielstrukturen ist größer denn je. Die fungale Sphingolipid-Biosynthese wurde bereits mehrfach als potenzielles Ziel antimykotischer Therapie diskutiert, allerdings bezieht sich die meiste Forschung hierzu auf C. albicans]. In vorliegender Arbeit wurden die Auswirkungen der Inhibition der Sphingolipid Biosynthese durch Myriocin auf C. auris und sein Resistenzverhalten untersucht und mit denen auf andere Candida Spezies verglichen. Sowohl die Mikrodilution als auch die Plattentropftests zeigten, dass C. auris verglichen mit anderen Candida Spezies besonders sensitiv auf die Anwesenheit von Myriocin reagierte und stärker im Wachstum gehemmt wurde. Der Survival Assay ergab für alle drei Spezies ein Absenken der CFU durch Myriocin, die Abweichungen zwischen den Stämmen waren jedoch unwesentlich. Unterschiede konnten in Vitalität und Vermehrung der verschiedenen Spezies unter Myriocineinfluss festgestellt werden. Aus der Lebend/Tot-Färbung ging hervor, dass Myriocin bei allen Stämmen zum Absterben von Candida Zellen führte, C. albicans und C. glabrata allerdings signifikant niedrigere Überlebensraten im Vergleich zu den C. auris Isolaten aufwiesen. Im Gegensatz dazu konnte mithilfe der FITC-Mikroskopie gezeigt werden, dass Candida Zellen unter Zugabe von Myriocin weniger Tochterzellen ausbildeten, was auf eine erschwerte oder zumindest verlangsamte Zellvermehrung hindeutet. Dabei schien das Wachstum der C. auris Stämme durch Myriocin deutlich eingeschränkter zu sein als das von C. albicans und C. glabrata. Durch weitere Mikroskopie und die Kombination aus Lebend/Tot Färbung mittels PI und FITC Färbung, sollte die Verteilung der toten Zellen auf Mutter- und Tochterzellen evaluiert werden. Hier konnte ein Trend zu einem vermehrten Zellsterben der Tochterzellen, vor allem für C. auris, festgestellt werden. Abschließende E-Tests für Amphotericin B, Anidulafungin und Fluconazol ergaben eine signifikante Herabsetzung der MHK für alle C. auris Isolate durch Myriocin. Die hier vorgestellten Ergebnisse und die durch mehrere Studien festgestellten Differenzen in der Sphingolipidkomposition von C. auris verglichen mit anderen Candida Spezies geben Hinweis darauf, dass Sphingolipide für Vitalität, Zellteilung und vor allem für die Wirkung einiger Antimykotika auf C. auris eine besondere, wenn nicht übergestellte Bedeutung haben könnten. Zwar wurde die Sphingolipidsynthese bereits mehrfach als potenzieller Angriffspunkt für die antifungale Therapie diskutiert, allerdings lediglich am Beispiel anderer Candida Spezies. Der Sphingolipidstoffwechsel könnte somit ein vielversprechender Ansatz für die Behandlung des sonst so therapieresistenten und lebensbedrohlichen Pilzes C. auris sein. N2 - Candida species are commensal organisms belonging to the normal human microflora, but can become pathogenic under certain conditions. Limitations in treatment due to an increasing number of resistant Candida species and the growing number of immunosuppressed patients are considered to be the main reasons for the increasing frequency of invasive candidiasis and systemic candidemia. C. auris, a species discovered in 2009, shows potential to cause nosocomial outbreaks in hospitals, limited susceptibility to numerous antifungals and a rapid spread across several continents. This leads to a need for new antifungal agents with different mechanisms of action and new targets. Fungal sphingolipid biosynthesis has been discussed several times as a potential target of antifungal therapy, however most research on this relates to C. albicans. In the present work, the effects of inhibition of sphingolipid biosynthesis by myriocin on C. auris and its impact on fungal susceptibility were investigated and compared with those on other Candida species. Both microdilution and plate droplet assays showed that C. auris was more sensitive to myriocin compared with other Candida species and showed severe growth defects. The survival assay showed a lowering of CFU by myriocin for all three species, but the differences between the strains were insignificant. Live/dead staining showed that myriocin led to the death of Candida cells in all strains, but C. albicans and C. glabrata had significantly lower survival rates compared to the C. auris isolates. In contrast, FITC microscopy showed that Candida cells produced fewer daughter cells when myriocin was added, indicating that cell proliferation was impeded or at least slowed. In this regard, the growth of C. auris strains appeared to be significantly more restricted by myriocin than that of C. albicans and C. glabrata. Further microscopy and the combination of live/dead staining using PI and FITC staining, was performed to evaluate the distribution of dead cells between mother and daughter cells. Here, a trend towards increased cell death of daughter cells, especially for C. auris, was observed. Final E-tests for amphotericin B, anidulafungin, and fluconazole revealed a significant reduction in MIC for all C. auris isolates by myriocin. These results and the differences in sphingolipid composition of C. auris compared with other Candida species established by several studies provide evidence that sphingolipids may have a special, if not superimposed, importance for viability, cell division, and especially for the suscteptibility of C. auris to some antifungals. It is true that sphingolipid synthesis has been discussed several times as a potential target for antifungal therapy, but only using other Candida species as examples. Sphingolipid metabolism could thus be a promising approach for the treatment of the therapy-resistant and life-threatening fungus C. auris. KW - Candida KW - Sphingolipide KW - Sphingolipidstoffwechsel KW - Multiresistenz KW - pathogene Pilze KW - Candida auris KW - Antimykotikaresistenz KW - antifungal susceptibility KW - myriocin Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-289121 ER - TY - JOUR A1 - Sattler, Janko A1 - Noster, Janina A1 - Brunke, Anne A1 - Plum, Georg A1 - Wiegel, Pia A1 - Kurzai, Oliver A1 - Meis, Jacques F. A1 - Hamprecht, Axel T1 - Comparison of two commercially available qPCR kits for the detection of Candida auris JF - Journal of Fungi N2 - Candida auris is an emerging pathogen with resistance to many commonly used antifungal agents. Infections with C. auris require rapid and reliable detection methods to initiate successful medical treatment and contain hospital outbreaks. Conventional identification methods are prone to errors and can lead to misidentifications. PCR-based assays, in turn, can provide reliable results with low turnaround times. However, only limited data are available on the performance of commercially available assays for C. auris detection. In the present study, the two commercially available PCR assays AurisID (OLM, Newcastle Upon Tyne, UK) and Fungiplex Candida Auris RUO Real-Time PCR (Bruker, Bremen, Germany) were challenged with 29 C. auris isolates from all five clades and eight other Candida species as controls. AurisID reliably detected C. auris with a limit of detection (LoD) of 1 genome copies/reaction. However, false positive results were obtained with high DNA amounts of the closely related species C. haemulonii, C. duobushaemulonii and C. pseudohaemulonii. The Fungiplex Candida Auris RUO Real-Time PCR kit detected C. auris with an LoD of 9 copies/reaction. No false positive results were obtained with this assay. In addition, C. auris could also be detected in human blood samples spiked with pure fungal cultures by both kits. In summary, both kits could detect C. auris-DNA at low DNA concentrations but differed slightly in their limits of detection and specificity. KW - qPCR KW - detection limits KW - sensitivity KW - strain specificity KW - commercial kits KW - Candida auris KW - Fungiplex Candida Auris KW - AurisID Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228879 SN - 2309-608X VL - 7 IS - 2 ER - TY - JOUR A1 - Mayr, Eva-Maria A1 - Ramírez-Zavala, Bernardo A1 - Krüger, Ines A1 - Morschhäuser, Joachim T1 - A Zinc Cluster Transcription Factor Contributes to the Intrinsic Fluconazole Resistance of Candida auris JF - mSphere N2 - ABSTRACT The recently emerged pathogenic yeast Candida auris is a major concern for human health, because it is easily transmissible, difficult to eradicate from hospitals, and highly drug resistant. Most C. auris isolates are resistant to the widely used antifungal drug fluconazole due to mutations in the target enzyme Erg11 and high activity of efflux pumps, such as Cdr1. In the well-studied, distantly related yeast Candida albicans, overexpression of drug efflux pumps also is a major mechanism of acquired fluconazole resistance and caused by gain-of-function mutations in the zinc cluster transcription factors Mrr1 and Tac1. In this study, we investigated a possible involvement of related transcription factors in efflux pump expression and fluconazole resistance of C. auris. The C. auris genome contains three genes encoding Mrr1 homologs and two genes encoding Tac1 homologs, and we generated deletion mutants lacking these genes in two fluconazole-resistant strains from clade III and clade IV. Deletion of TAC1b decreased the resistance to fluconazole and voriconazole in both strain backgrounds, demonstrating that the encoded transcription factor contributes to azole resistance in C. auris strains from different clades. CDR1 expression was not or only minimally affected in the mutants, indicating that Tac1b can confer increased azole resistance by a CDR1-independent mechanism. IMPORTANCE Candida auris is a recently emerged pathogenic yeast that within a few years after its initial description has spread all over the globe. C. auris is a major concern for human health, because it can cause life-threatening systemic infections, is easily transmissible, and is difficult to eradicate from hospital environments. Furthermore, C. auris is highly drug resistant, especially against the widely used antifungal drug fluconazole. Mutations in the drug target and high activity of efflux pumps are associated with azole resistance, but it is not known how drug resistance genes are regulated in C. auris. We have investigated the potential role of several candidate transcriptional regulators in the intrinsic fluconazole resistance of C. auris and identified a transcription factor that contributes to the high resistance to fluconazole and voriconazole of two C. auris strains from different genetic clades, thereby providing insight into the molecular basis of drug resistance of this medically important yeast." KW - Candida auris KW - fluconazole resistance KW - transcription factor Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-229937 VL - 5 IS - 2 ER -